Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Shares of Novavax Inc. NVAX rallied 6.11% to $6.34 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index COMP rising 4.35% to ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

Novavax Inc. closed 74.96% below its 52-week high of $23.86, which the company reached on June 6th.

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Novavax (NASDAQ:NVAX) pivots back to profitability after delivering a $666.7 million revenue haul in Q1surpassing estimates by $322.8 millionand lifting its full-year revenue forecast ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2025. Novavax, Inc. (Nasdaq: NVAX) today announced that it will ...

On Thursday, Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million. Higher product sales for ...